Politician trade (House)

AbbVie (ABBV): Rep. Lisa C. McClain (MI09) disclosed a sale $1K–$15K

Rep. Lisa C. McClain (MI09) disclosed a sale of AbbVie in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
21 days
Disclosure lag
Traded
Oct 31, 2025
Disclosed
Nov 21, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 23, 2024CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  2. Jan 24, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  3. Apr 28, 2025CongressDisclosed purchase of ABBV — reported range $1,001 - $15,000
  4. Aug 11, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  5. Aug 14, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  6. Aug 22, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  7. Sep 3, 2025FDAFDA drug approval: Skyrizi
  8. Sep 3, 2025FDAFDA drug approval: Skyrizi
  9. Oct 3, 2025Company filing · Form 8-K · ResultsReported its results
  10. Oct 10, 2025FDAFDA drug approval: Rinvoq
  11. Oct 30, 2025Federal contract · $21K obligatedDepartment of Defense awarded AbbVie: $21K obligated to date
  12. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  13. Oct 31, 2025 · this disclosureCongressDisclosed sale of ABBV — reported range $1,001 - $15,000

What came next

  1. Oct 31, 2025Company filing · Form 8-K · ResultsReported its results
  2. Nov 4, 2025FDAFDA drug approval: Linzess
  3. Nov 10, 2025Layoff notice · 5996 Gleason Drive Dublin CA 94568Layoff notice filed in CA: 48 employees
  4. Nov 10, 2025Layoff notice · 7041 Las Positas Road Livermore CA 94551Layoff notice filed in CA: 9 employees
  5. Nov 10, 2025Layoff notice · 4410 Rosewood Drive Pleasonton CA 94588Layoff notice filed in CA: 2 employees
  6. Nov 13, 2025CongressDisclosed partial sale of ABBV — reported range $1,001 - $15,000
  7. Dec 8, 2025Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $3.8K obligated to date
  8. Dec 8, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  9. Dec 12, 2025Federal contract · $24K obligatedDepartment of Defense awarded AbbVie: $24K obligated to date
  10. Dec 18, 2025FDAFDA drug approval: Vraylar
  11. Dec 18, 2025FDAFDA drug approval: Vraylar
  12. Dec 18, 2025FDAFDA drug approval: Vraylar
  13. Dec 18, 2025FDAFDA drug approval: Vraylar
  14. Dec 18, 2025CongressDisclosed sale of ABBV — reported range $1,001 - $15,000
  15. Dec 22, 2025Government · Federal Register noticeCertain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Institution of Investigation
  16. Jan 7, 2026Company filing · Form 8-K · ResultsReported its results
  17. Jan 16, 2026FDAFDA device clearance: Natrelle 133S Tissue Expanders
  18. Jan 20, 2026Federal contract · $4K obligatedDepartment of Defense awarded AbbVie: $4K obligated to date
  19. Feb 4, 2026Company filing · Form 8-K · ResultsReported its results
  20. Feb 19, 2026FDAFDA drug approval: Venclexta
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for AbbVie

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ABBV page.

Other recent filings by Rep. Lisa C. McClain (MI09)

The full history of Rep. Lisa C. McClain (MI09) is on the profile page.

How this filing works

Explore the data

Common questions

Which member of Congress traded AbbVie (ABBV) stock, and how much?

Rep. Lisa C. McClain (MI09) disclosed a sale of AbbVie in the $1K–$15K range. Reported range, not an exact amount, Spouse account.

When did it happen, and when was it made public?

Traded: Oct 31, 2025. Disclosed: Nov 21, 2025. That is 21 days between the two dates.

Why is the amount a range and not an exact figure?

Members of Congress report each trade in a bracket set by law ($1,001 to $15,000, $15,001 to $50,000, and so on), never an exact amount. OQRO keeps the bracket as filed and does not estimate a figure inside it.

Where does this information come from?

From the House Clerk periodic transaction report, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about AbbVie recently?

For AbbVie, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 1 Congress trade report and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the ABBV page.

Does this mean ABBV stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at AbbVie

Everything OQRO holds on this company is on its ABBV page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data